

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Fluocinolone acetonide intravitreal implant for treating chronic diabetic oedema in phakic eyes after an inadequate response to previous therapy (TA613)
Policy No:	PCN 471/2019
Date of Issue	6th December 2019
Review Date:	December 2019
Recommendations:	
<p>The Area Prescribing Committee considers fluocinolone acetonide intravitreal implant should be considered BLACK on the traffic light system for the indication of treating chronic diabetic oedema in phakic eyes after an inadequate response to previous therapy in line with NICE TA613.</p> <p>Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.</p>	
Key Considerations:	
<ul style="list-style-type: none"> Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy https://www.nice.org.uk/guidance/ta613 	
Date taken to Area Prescribing Committee	4 th December 2019
Agreed by APC members	

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG